AU2026200410A1 — Topical treatment of vitiligo by a jak inhibitor
Assigned to Incyte Corp · Expires 2026-02-12 · 0y expired
What this patent protects
A method of treating vitiligo in an affected area of a patient comprising: topically administering to the affected skin area of the patient in need thereof a pharmaceutical composition comprising 0.5% or 1.5% w/w ruxolitinib, or a pharmaceutically acceptable salt thereof, on a fr…
USPTO Abstract
A method of treating vitiligo in an affected area of a patient comprising: topically administering to the affected skin area of the patient in need thereof a pharmaceutical composition comprising 0.5% or 1.5% w/w ruxolitinib, or a pharmaceutically acceptable salt thereof, on a free base basis, twice per day and the vitiligo is nonsegmental vitiligo, wherein the affected skin area comprises at least one of lower extremities, trunk, and feet of the patient, and wherein the method does not comprise administering phototherapy.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.